FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217164085> ?p ?o ?g. }

• W3217164085 abstract "The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), spirometry, diffusion capacity of the lungs (DLCO), and chest-CT were performed at 23 Norwegian hospitals included in the NOR-SOLIDARITY trial, an open-labelled, randomised clinical trial, investigating the efficacy of remdesivir and hydroxychloroquine (HCQ). Thirty-eight percent had a CAT-score ≥ 10. DLCO was below the lower limit of normal in 29.6%. Ground-glass opacities were present in 39.8% on chest-CT, parenchymal bands were found in 41.7%. At admission, low pO2/FiO2 ratio, ICU treatment, high viral load, and low antibody levels, were predictors of a poorer pulmonary outcome after 3 months. High levels of matrix metalloproteinase (MMP)-9 during hospitalisation and at 3 months were associated with persistent CT-findings. Except for a negative effect of remdesivir on CAT-score, we found no effect of remdesivir or HCQ on long-term pulmonary outcomes. Three months after hospital admission for COVID-19, a high prevalence of respiratory symptoms, reduced DLCO, and persistent CT-findings was observed. Low pO2/FiO2 ratio, ICU-admission, high viral load, low antibody levels, and high levels of MMP-9 were associated with a worse pulmonary outcome." @default.
• W3217164085 created "2021-12-06" @default.
• W3217164085 creator A5000241903 @default.
• W3217164085 creator A5000960665 @default.
• W3217164085 creator A5002578091 @default.
• W3217164085 creator A5003059661 @default.
• W3217164085 creator A5003071345 @default.
• W3217164085 creator A5006178262 @default.
• W3217164085 creator A5008352835 @default.
• W3217164085 creator A5008739377 @default.
• W3217164085 creator A5009417245 @default.
• W3217164085 creator A5012236679 @default.
• W3217164085 creator A5013106012 @default.
• W3217164085 creator A5018595845 @default.
• W3217164085 creator A5018839831 @default.
• W3217164085 creator A5019936964 @default.
• W3217164085 creator A5020239313 @default.
• W3217164085 creator A5020571500 @default.
• W3217164085 creator A5021619556 @default.
• W3217164085 creator A5021654392 @default.
• W3217164085 creator A5024469667 @default.
• W3217164085 creator A5025854200 @default.
• W3217164085 creator A5028388510 @default.
• W3217164085 creator A5029518876 @default.
• W3217164085 creator A5032788007 @default.
• W3217164085 creator A5032975193 @default.
• W3217164085 creator A5034164090 @default.
• W3217164085 creator A5035287782 @default.
• W3217164085 creator A5037749191 @default.
• W3217164085 creator A5037957678 @default.
• W3217164085 creator A5039345691 @default.
• W3217164085 creator A5039625009 @default.
• W3217164085 creator A5040928251 @default.
• W3217164085 creator A5041800464 @default.
• W3217164085 creator A5042702052 @default.
• W3217164085 creator A5042730899 @default.
• W3217164085 creator A5043335601 @default.
• W3217164085 creator A5048568773 @default.
• W3217164085 creator A5049781197 @default.
• W3217164085 creator A5050617710 @default.
• W3217164085 creator A5051428768 @default.
• W3217164085 creator A5051644982 @default.
• W3217164085 creator A5052927725 @default.
• W3217164085 creator A5055448626 @default.
• W3217164085 creator A5057109243 @default.
• W3217164085 creator A5057630052 @default.
• W3217164085 creator A5057914203 @default.
• W3217164085 creator A5059084720 @default.
• W3217164085 creator A5059349342 @default.
• W3217164085 creator A5060024538 @default.
• W3217164085 creator A5060600695 @default.
• W3217164085 creator A5062211998 @default.
• W3217164085 creator A5062480277 @default.
• W3217164085 creator A5062493942 @default.
• W3217164085 creator A5067373982 @default.
• W3217164085 creator A5070988185 @default.
• W3217164085 creator A5070997478 @default.
• W3217164085 creator A5071601713 @default.
• W3217164085 creator A5072176721 @default.
• W3217164085 creator A5072182283 @default.
• W3217164085 creator A5072208856 @default.
• W3217164085 creator A5073204885 @default.
• W3217164085 creator A5073484377 @default.
• W3217164085 creator A5074659958 @default.
• W3217164085 creator A5076280447 @default.
• W3217164085 creator A5076836210 @default.
• W3217164085 creator A5077105911 @default.
• W3217164085 creator A5078359202 @default.
• W3217164085 creator A5080272188 @default.
• W3217164085 creator A5082568359 @default.
• W3217164085 creator A5083214115 @default.
• W3217164085 creator A5083694918 @default.
• W3217164085 creator A5085513171 @default.
• W3217164085 creator A5085867520 @default.
• W3217164085 creator A5086151059 @default.
• W3217164085 creator A5087287890 @default.
• W3217164085 creator A5088515681 @default.
• W3217164085 creator A5090166045 @default.
• W3217164085 date "2021-12-01" @default.
• W3217164085 modified "2023-10-18" @default.
• W3217164085 title "Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9" @default.
• W3217164085 cites W144141289 @default.
• W3217164085 cites W1536748425 @default.
• W3217164085 cites W1977958018 @default.
• W3217164085 cites W2001818756 @default.
• W3217164085 cites W2099449365 @default.
• W3217164085 cites W2102634410 @default.
• W3217164085 cites W2108329413 @default.
• W3217164085 cites W2130158896 @default.
• W3217164085 cites W2143604872 @default.
• W3217164085 cites W2155078044 @default.
• W3217164085 cites W2157968241 @default.
• W3217164085 cites W2561638494 @default.
• W3217164085 cites W2605314287 @default.
• W3217164085 cites W2618347363 @default.
• W3217164085 cites W2745451136 @default.
• W3217164085 cites W2755145368 @default.
• W3217164085 cites W2981067716 @default.
• W3217164085 cites W3004280078 @default.
• W3217164085 cites W3009885589 @default.

• next